If validation testing goes to plan, the firm believes it can have an inexpensive coronavirus test available for use at the point of care in about six months.
The developer said that use of gold nanoparticles enables use at the point of care and inexpensive signal amplification that eliminates traditional equipment.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.
